SLXN

Silexion Therapeutics Corp

0.1452

Oct 30 • 3:59 PM ET +0.0029 (2.04%)

0.1451

Aftermarket • 7:27 PM ET -0.0001 (-0.07%)

Healthcare Biotechnology Israel Nano NASD

Peers: PHIO RNAZ PMCB PPCB RNXT ELTX PPBT ONCY SLN ERAS

Scroll to Statements

Index	-
Market Cap	2.20M
Enterprise Value	1.35M
Income	-13.96M
Sales	0.00M
Book/sh	0.04
Cash/sh	0.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Apr 07, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.89
P/C	0.98
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.94
Current Ratio	0.94
Debt/Eq	35.25
LT Debt/Eq	5.75
Option/Short	No / Yes

EPS (ttm)	-56.54
EPS next Y	-20.25
EPS next Q	-9.10
EPS this Y	45.93%
EPS next Y	58.20%
EPS next 5Y	41.98%
EPS past 3/5Y	- -38.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.10%
Sales Y/Y TTM	-
EPS Q/Q	88.04%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	75.61% -

Insider Own	40.68%
Insider Trans	0.00%
Inst Own	0.13%
Inst Trans	0.10%
ROA	-277.96%
ROE	-17021.95%
ROIC	-5169.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-21.64%
SMA50	-48.92%
SMA200	-97.83%
Trades

Shs Outstand	15.21M
Shs Float	9.02M
Short Float	1.80%
Short Ratio	0.02
Short Interest	0.16M
52W High	34.60 -99.58%
52W Low	0.14 2.54%
Volatility	15.70% 14.58%
ATR (14)	0.04
RSI (14)	32.14
Beta	-0.37
Rel Volume	0.07
Avg Volume	10.09M
Volume	740,801

Perf Week	-23.11%
Perf Month	-47.96%
Perf Quarter	-92.55%
Perf Half Y	-97.57%
Perf YTD	-99.24%
Perf Year	-99.56%
Perf 3Y	-100.00%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	2.00
Target Price	50.00
Prev Close	0.14
Price	0.15
Change %	2.04%

Sep-30-26 08:00AM	Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer (GlobeNewswire) -12.91%
Sep-29-26 08:03AM	Silexion Therapeutics Announces Exercise of Warrants (GlobeNewswire) +28.18%
Sep-28-26 08:30AM	Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers (GlobeNewswire)
Sep-09-26 09:00AM	Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences (GlobeNewswire)
Aug-25-26 08:43AM	After Moderna's $44B Oncology Win, Silexion's Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) (FinanceWire)
08:45AM	Loading…
Aug-14-26 08:45AM	Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -8.65%
Aug-11-26 08:01PM	Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering (GlobeNewswire) -31.00% -56.13%
Aug-10-26 03:21PM	Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) (FinanceWire) -19.79%
Aug-04-26 09:15AM	Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers (GlobeNewswire)
Jul-29-26 10:35AM	Silexion Therapeutics Initiates Phase 2/3 Trial of SIL204 in Pancreatic Cancer (InvestorsHub) -34.69%
09:06AM	Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) (FinanceWire)
07:00AM	Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center (GlobeNewswire)
Jun-23-26 08:40AM	Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Jun-16-26 04:30PM	Silexion Therapeutics to Attend BIO International Convention 2026 (GlobeNewswire) +7.01%
May-26-26 08:30AM	Silexion Therapeutics Announces 1-for-10 Reverse Share Split (GlobeNewswire) -14.14%
08:30AM	Loading…
May-18-26 08:30AM	Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -5.36%
May-15-26 08:27AM	Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds (GlobeNewswire) -42.06%
May-14-26 09:27AM	Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer (GlobeNewswire) -9.31%
May-13-26 08:00AM	Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center (GlobeNewswire) -5.01%
Apr-28-26 08:45AM	Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer (GlobeNewswire) -12.75%
Mar-24-26 09:46AM	Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer (GlobeNewswire) +5.51%
Mar-17-26 05:01PM	Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-26 08:00AM	Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting (GlobeNewswire)
Jan-21-26 08:30AM	Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit (GlobeNewswire) -5.80%
Jan-06-26 07:30AM	Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 (GlobeNewswire)
Dec-16-25 08:40AM	Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Dec-02-25 08:00AM	Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer (GlobeNewswire) -7.61%
Nov-26-25 07:30AM	Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (GlobeNewswire) +20.42%
Nov-25-25 09:15AM	Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer (GlobeNewswire) +7.62%
Nov-12-25 09:00AM	Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
08:40AM	Loading…
Sep-30-25 08:40AM	Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer (GlobeNewswire)
Sep-25-25 08:45AM	Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-11-25 09:17AM	Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering (GlobeNewswire) +9.92%
07:00AM	Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration (GlobeNewswire)
Sep-04-25 09:25AM	Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 (GlobeNewswire)
Sep-02-25 08:45AM	Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-12-25 08:00AM	Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 08:00PM	Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds (GlobeNewswire) +31.98% -37.88%
09:55AM	Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation (GlobeNewswire)
Jul-16-25 08:44AM	Silexion Therapeutics Announces 1-for-15 Reverse Share Split (GlobeNewswire) -8.56%
Jul-09-25 08:30AM	Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines (GlobeNewswire) +12.33%
May-30-25 09:10AM	Silexion Therapeutics announces preclinical results on SIL204 (TipRanks) +8.33%
May-29-25 11:43PM	Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors (Insider Monkey)
09:05AM	Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers (GlobeNewswire)
May-21-25 08:45AM	Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer (GlobeNewswire)
May-13-25 04:45PM	Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-25 09:20AM	Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities (GlobeNewswire) +46.51%
Mar-28-25 08:30AM	Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data (GlobeNewswire)
Mar-21-25 08:30AM	Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference (GlobeNewswire)
Mar-18-25 04:29PM	Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.20%
Mar-17-25 08:15AM	PESG Report: Silexion Therapeutics Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis Signaling a Potential Paradigm Shift in Cancer Treatment (Business Wire)
Mar-05-25 08:30AM	Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models (GlobeNewswire) +30.63%
Mar-03-25 08:30AM	PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational (Business Wire)
Feb-25-25 08:30AM	Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204 (GlobeNewswire) +64.00%
Jan-29-25 05:30PM	Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds (GlobeNewswire) +132.59% -34.71%
09:59AM	PESG Report: Silexion Therapeutics Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market (Business Wire)
Jan-28-25 08:29AM	Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models (GlobeNewswire) +132.76%
Jan-16-25 11:04AM	PESG Market Update: Silexion Therapeutics SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments (Business Wire) -39.74%
Jan-15-25 08:00PM	Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -11.86%
04:01PM	Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies (GlobeNewswire)
Jan-13-25 07:50AM	Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-18-24 06:35AM	Silexion Therapeutics, Evonik collaborate on siRNA formulation development (TipRanks) -26.21%
Dec-17-24 09:36AM	PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises (Business Wire) -10.77%
06:30AM	Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development (GlobeNewswire)
Dec-10-24 08:30AM	Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors (GlobeNewswire)
Nov-22-24 04:30PM	Silexion Therapeutics Announces 1-for-9 Reverse Share Split (GlobeNewswire)
Nov-20-24 08:30AM	Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +47.26%
Nov-14-24 08:30AM	Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE) -8.73%
Oct-09-24 05:35PM	Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE) -11.93% -5.98%
Oct-01-24 06:45AM	Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies (Business Wire) +5.90%
Sep-24-24 07:30AM	Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER in Non-Resectable Pancreatic Cancer (Business Wire) -16.28%
Sep-09-24 07:32AM	PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers (Business Wire) +11.61%
Sep-03-24 04:05PM	Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference (GlobeNewswire) -24.66% -10.98%
Aug-15-24 04:05PM	Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination (GlobeNewswire) -13.21% -79.39%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shirvan Mitchell	CSO and CDO	Mar 26 '26	Sale	1.36	22,818	31,032	27,889	Mar 30 05:29 PM

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Chairman & CEOMr. Ilan Hadar M.B.A.

EVP of Finance AffairsMs. Mirit Horenshtein Hadar

Ph.D.Dr. Mitchell Shirvan M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLXN

Silexion Therapeutics Corp

Upgrade your Finviz experience